These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1169 related items for PubMed ID: 9973433

  • 21. Receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide in the goose cerebral cortex.
    Zawilska JB, Niewiadomski P, Nowak JZ.
    Pol J Pharmacol; 2004; 56(2):203-11. PubMed ID: 15156071
    [Abstract] [Full Text] [Related]

  • 22. Pituitary adenylate cyclase activating polypeptide (PACAP) and vasoactive intestinal peptide (VIP) stimulate interleukin-6 production through the third subtype of PACAP/VIP receptor in rat bone marrow-derived stromal cells.
    Cai Y, Xin X, Shim GJ, Mokuno Y, Uehara H, Yamada T, Agui T, Matsumoto K.
    Endocrinology; 1997 Jun; 138(6):2515-20. PubMed ID: 9165043
    [Abstract] [Full Text] [Related]

  • 23. Inhibition of IFN-gamma-induced janus kinase-1-STAT1 activation in macrophages by vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide.
    Delgado M, Ganea D.
    J Immunol; 2000 Sep 15; 165(6):3051-7. PubMed ID: 10975815
    [Abstract] [Full Text] [Related]

  • 24. VIP/PACAP preferentially attract Th2 effectors through differential regulation of chemokine production by dendritic cells.
    Delgado M, Gonzalez-Rey E, Ganea D.
    FASEB J; 2004 Sep 15; 18(12):1453-5. PubMed ID: 15231725
    [Abstract] [Full Text] [Related]

  • 25. Vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide inhibit the MEKK1/MEK4/JNK signaling pathway in LPS-stimulated macrophages.
    Delgado M, Ganea D.
    J Neuroimmunol; 2000 Oct 02; 110(1-2):97-105. PubMed ID: 11024538
    [Abstract] [Full Text] [Related]

  • 26. cAMP activation by PACAP/VIP stimulates IL-6 release and inhibits osteoblastic differentiation through VPAC2 receptor in osteoblastic MC3T3 cells.
    Nagata A, Tanaka T, Minezawa A, Poyurovsky M, Mayama T, Suzuki S, Hashimoto N, Yoshida T, Suyama K, Miyata A, Hosokawa H, Nakayama T, Tatsuno I.
    J Cell Physiol; 2009 Oct 02; 221(1):75-83. PubMed ID: 19496170
    [Abstract] [Full Text] [Related]

  • 27. Characterization and expression of different pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide receptors in rat ovarian follicles.
    Vaccari S, Latini S, Barberi M, Teti A, Stefanini M, Canipari R.
    J Endocrinol; 2006 Oct 02; 191(1):287-99. PubMed ID: 17065411
    [Abstract] [Full Text] [Related]

  • 28. Pituitary adenylate cyclase-activating polypeptide receptors mediating insulin secretion in rodent pancreatic islets are coupled to adenylate cyclase but not to PLC.
    Jamen F, Puech R, Bockaert J, Brabet P, Bertrand G.
    Endocrinology; 2002 Apr 02; 143(4):1253-9. PubMed ID: 11897681
    [Abstract] [Full Text] [Related]

  • 29. A cloned frog vasoactive intestinal polypeptide/pituitary adenylate cyclase-activating polypeptide receptor exhibits pharmacological and tissue distribution characteristics of both VPAC1 and VPAC2 receptors in mammals.
    Alexandre D, Anouar Y, Jegou S, Fournier A, Vaudry H.
    Endocrinology; 1999 Mar 02; 140(3):1285-93. PubMed ID: 10067855
    [Abstract] [Full Text] [Related]

  • 30. Properties of the pituitary adenylate cyclase-activating polypeptide I and II receptors, vasoactive intestinal peptide1, and chimeric amino-terminal pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal peptide1 receptors: evidence for multiple receptor states.
    Van Rampelbergh J, Gourlet P, De Neef P, Robberecht P, Waelbroeck M.
    Mol Pharmacol; 1996 Dec 02; 50(6):1596-604. PubMed ID: 8967982
    [Abstract] [Full Text] [Related]

  • 31. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit nuclear factor-kappa B-dependent gene activation at multiple levels in the human monocytic cell line THP-1.
    Delgado M, Ganea D.
    J Biol Chem; 2001 Jan 05; 276(1):369-80. PubMed ID: 11029467
    [Abstract] [Full Text] [Related]

  • 32. VPAC2 receptors mediate vasoactive intestinal peptide-induced neuroprotection against neonatal excitotoxic brain lesions in mice.
    Rangon CM, Goursaud S, Medja F, Lelièvre V, Mounien L, Husson I, Brabet P, Jégou S, Janet T, Gressens P.
    J Pharmacol Exp Ther; 2005 Aug 05; 314(2):745-52. PubMed ID: 15872042
    [Abstract] [Full Text] [Related]

  • 33. Activation of VPAC1 receptors by VIP and PACAP-27 in human bronchial epithelial cells induces CFTR-dependent chloride secretion.
    Dérand R, Montoni A, Bulteau-Pignoux L, Janet T, Moreau B, Muller JM, Becq F.
    Br J Pharmacol; 2004 Feb 05; 141(4):698-708. PubMed ID: 14744818
    [Abstract] [Full Text] [Related]

  • 34. VPAC2-R mediates the lipolytic effects of pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide in primary rat adipocytes.
    Akesson L, Ahrén B, Edgren G, Degerman E.
    Endocrinology; 2005 Feb 05; 146(2):744-50. PubMed ID: 15514088
    [Abstract] [Full Text] [Related]

  • 35. Receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide in turkey cerebral cortex: characterization by [125I]-VIP binding and effects on cyclic AMP synthesis.
    Zawilska JB, Niewiadomski P, Nowak JZ.
    Gen Comp Endocrinol; 2004 Jun 05; 137(2):187-95. PubMed ID: 15158130
    [Abstract] [Full Text] [Related]

  • 36. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit the production of inflammatory mediators by activated microglia.
    Delgado M, Leceta J, Ganea D.
    J Leukoc Biol; 2003 Jan 05; 73(1):155-64. PubMed ID: 12525573
    [Abstract] [Full Text] [Related]

  • 37. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide: players in innate and adaptive immunity.
    Ganea D, Rodriguez R, Delgado M.
    Cell Mol Biol (Noisy-le-grand); 2003 Mar 05; 49(2):127-42. PubMed ID: 12887096
    [Abstract] [Full Text] [Related]

  • 38. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide stimulate the induction of Th2 responses by up-regulating B7.2 expression.
    Delgado M, Leceta J, Gomariz RP, Ganea D.
    J Immunol; 1999 Oct 01; 163(7):3629-35. PubMed ID: 10490956
    [Abstract] [Full Text] [Related]

  • 39. Characterization of vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptors in human benign hyperplastic prostate.
    Solano RM, Carmena MJ, Carrero I, Cavallaro S, Roman F, Hueso C, Travali S, Lopez-Fraile N, Guijarro LG, Prieto JC.
    Endocrinology; 1996 Jul 01; 137(7):2815-22. PubMed ID: 8770902
    [Abstract] [Full Text] [Related]

  • 40. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide modulate endotoxin-induced IL-6 production by murine peritoneal macrophages.
    Martínez C, Delgado M, Pozo D, Leceta J, Calvo JR, Ganea D, Gomariz RP.
    J Leukoc Biol; 1998 May 01; 63(5):591-601. PubMed ID: 9581803
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 59.